Comparison between single subcutaneous glargine injection and continuous regular insulin infusion for glycemic control in critically ill patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20160126004

Enrollment

Unknown

Registered

2016-01-26

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To determine whether a single subcutaneous glargine injection with 100% dose transition is not inferior to continuous regular insulin (RI) infusion for blood glucose control in critically ill patients Glycemic control&#44

Interventions

Insulin Glargine subcutaneous injection once daily dose by the dosage of 100% of previous 24 hours of regular insulin infusion dose.

Experimental Drug

Insulin Glargine single dose

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Adult patient with - admitted to the intensive care unit with hyperglycemia and required insulin infusion (blood glucose>=140 mg/dL) - required constant rate of continuous regular insulin infusion for 12 consecutive hours - previous 12 hours blood glucose level were in the proper range (80-200 mg/dL) - trend to receive constant glucose intake rate

Exclusion criteria

Exclusion criteria: Adult patient who - trend to change in glucose intake rate - deteriorated hemodynamic status - diabetic ketoacidosis or hyperosmolar coma

Design outcomes

Primary

Measure	Time frame
Blood glucose level every 2 hours for 24 hours 24 hours Blood sugar mg/dl	—

Secondary

Measure	Time frame
nil nil nil	—

Countries

Thailand

Contacts

Public ContactRungsun Bhurayanontachai

ICU Songklanagaridn hospital

rungsun2346@gmail.com0815990583

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026